CD8A and neoplasm: The combination of a Notch inhibitor with anti-PD-L1 therapy resulted in a significant increase in CD8+ T cell infiltration and reduction in Ki67 staining, which cumulatively reduced immunosuppression and improved anti-tumor efficacy.